Craig Erickson, MD, is a leading expert in Fragile X Syndrome (FXS) and the director of the Fragile X Research and Treatment Center. His primary research focus is investigating novel approaches to the treatment of FXS. He has consistently received funding support from various sources, including FRAXA Research Foundation, The John Merck Foundation, Novartis Pharmaceuticals, and Seaside Therapeutics. Dr. Erickson is particularly interested if a medication, acamprosate, an mGluR5 antagonist, can improve social interaction and communication in individuals with FXS.
Use of Acamprosate in Individuals with Fragile X:
Dr. Erickson has just begun to investigate if acamprosate use in individuals with FXS can improve social interaction and communication. Dr. Erickson began this research three years ago at Indiana University School and Medicine and has been continuing his efforts at Cincinnati Children's. Dr. Erickson recently received a large grant to support is investigation on acamprosate.
Acamprosate is a FDA approved medication to treat alcoholism in adults. Animal research has shown that this medication acts as an antagonist at the mGlur5 receptor, which possibly plays a role in the FXS mutation. At Indiana University, Dr. Erickson completed and published several studies investigating this medication.